Transderm Scop® — Competitive Intelligence Brief

Transderm Scop® (Transderm Scop®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Gastroenterology / Anesthesia.

marketed Anticholinergic agent Muscarinic acetylcholine receptor (non-selective antagonist) Gastroenterology / Anesthesia Small molecule

Target snapshot

Transderm Scop® (Transderm Scop®) — University of Iowa. Scopolamine blocks muscarinic acetylcholine receptors to prevent nausea and vomiting by reducing vestibular and chemoreceptor trigger zone activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Transderm Scop® TARGET	Transderm Scop®	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (non-selective antagonist)
Atropine sulfate and epinephrine	Atropine sulfate and epinephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent and sympathomimetic amine combination	Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)
ACs	ACs	GlaxoSmithKline	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (non-selective or subtype-specific)
Solifenacin plus Tamsulosin	Solifenacin plus Tamsulosin	Soonchunhyang University Hospital	marketed	Anticholinergic agent + alpha-1A adrenergic antagonist combination	M3 muscarinic receptor; alpha-1A adrenergic receptor
Bencycloquidium Bromide Nasal Spray	Bencycloquidium Bromide Nasal Spray	Yingu Pharmaceutical Co., Ltd	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M3)
Oxybutynin ER	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)
Active B&O suppository of belladonna	Active B&O suppository of belladonna	Edgar LeClaire, MD	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1-M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class